Story
Boston Scientific Shares Drop After Cyberattack Disrupts Global Operations

Boston Scientific (NYSE: BSX) shares fell 4.6% to $47.57 on Wednesday after the company disclosed it was hit by a cybersecurity incident that disrupted its global order processing and shipping capabilities. The sell-off exacerbates an already challenging year for the medtech firm, with its stock now down 55% year-to-date and trading just 12% above its 52-week low.
A Pattern of Attacks in Medtech
The incident at Boston Scientific follows a similar event that impacted competitor Stryker Corp (NYSE: SYK) in March 2026. Stryker's experience provides a potential roadmap for investors assessing the operational and financial fallout:
- Initial Impact: Stryker's cyberattack dragged its first-quarter revenue down by approximately 5%.
- Lingering Costs: The company reported that remediation costs continued to affect operating margins into the second quarter.
- Stock Recovery: Five months after its incident, Stryker's stock remains 17% below its 52-week high, indicating a prolonged recovery period for investor confidence.
This year has seen a notable increase in cyberattacks across the healthcare sector, with companies like Novo Nordisk and iRhythm Holdings also reporting security breaches. The pattern suggests a typical operational recovery timeline of four to six months.
AdAnalyst Outlook Compounded by Headwinds
Wall Street analysts are divided on the incident's long-term implications, largely due to Boston Scientific's pre-existing challenges. Before the attack, the company had already slashed its 2027 revenue growth forecasts from 8% to 4% and faced headwinds related to its WATCHMAN device and electrophysiology business.
Stifel reiterated its Buy rating, stating it "would not view a cybersecurity-related guidance change as reflecting negatively on fundamental performance." Similarly, TD Cowen maintained a Buy rating, noting the reset in estimates has created a "favorable risk/reward." However, Argus downgraded the stock to Hold, citing the cyber incident as a compounding factor on top of existing fundamental weaknesses.
For investors, the key difference from the Stryker precedent is the starting point. Stryker was a fundamentally strong company when it was attacked, whereas Boston Scientific is already in a downturn. The market may therefore interpret this operational disruption not as an isolated event, but as confirmation of deeper challenges facing the company.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.